Compare FirstEnergy Corp. (FE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Sana Biotechnology Inc — how do they compare? FirstEnergy Corp. trades at $46.9 (market cap $27.10B), while Sana Biotechnology Inc trades at $3.81 (market cap $1.13B). The key difference: FirstEnergy Corp. is far larger — about 24× Sana Biotechnology Inc's market cap, and FirstEnergy Corp. pays a 3.97% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| FE | SANA | |
|---|---|---|
Market Cap | $27.10B | $1.13B |
Sector | Utilities | Health |
52-Week High | $51.91 | $5.92 |
52-Week Low | $42.83 | $2.68 |
Enterprise Value | $56.02B | $1.05B |
Dividend Yield | 3.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $46.76, down 1.5% with bearish technical signals despite recent earnings beat. The utility shows steady revenue growth to $15.09B (2025) and maintains a 6.86% net margin, though EPS performance has been mixed. Analyst consensus is divided with 12 Buy and 16 Hold ratings, targeting $52.67 average price. Recent news highlights institutional buying and grid investments to support rising data center demand.
Investment outlook balances growth from infrastructure spending and data center demand against execution risks and debt levels. The stock offers value below analyst targets with dividend income, but faces headwinds from capital expenditure requirements and interest rate sensitivity. Current valuation at P/E 25.05 appears reasonable for sector growth prospects.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
